4 completed, 3 active not recruiting, 3 recruiting, 1 terminated. 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 4, Active not recruiting 3, Recruiting 3, Terminated 1, Unknown 1 |
Follow Adenocarcinoma, Clear Cell: new trials by email Literature Review of Adenocarcinoma, Clear Cell trials Research Report on Adenocarcinoma, Clear Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer Sacituzumab tirumotecan, Pembrolizumab - Ovarian Clear Cell Carcinoma, Metastatic Ovarian Cancer | Phase 2 | Recruiting | Tufts Medical Center | 50 | 2026-09-01 | 2026-09-16 |
| A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy 3 cycles chemotherapy instead of 6 cycles chemotherapy, 6 cycles chemotherapy - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Recruiting | North Eastern German Society of Gynaecological Oncology | 640 | 2024-10-11 | 2026-10-23 |
| Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring Oncological Follow-up - Stage I Testicular Seminoma, Stage I Testicular Nonseminomatous Germ Cell Tumor | Phase 2 | Recruiting | Centre Oscar Lambret | 88 | 2024-02-28 | 2026-03-18 |
| A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) Dostarlimab, Bevacizumab, Doxorubicin - Ovarian Neoplasms, Endometrial Neoplasms | Phase 2 | Active not recruiting | Yonsei University | 198 | 2024-01-22 | 2026-11-02 |
| A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies vudalimab - Ovarian Cancer, Clear Cell Carcinoma | Phase 2 | Active not recruiting | Xencor, Inc. | 170 | 2022-07-21 | 2025-02-07 |
| BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas Nivolumab, Ipilimumab - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Active not recruiting | Brown University | 46 | 2018-04-30 | 2026-08-20 |
| A Study of Nivolumab in Selected Uterine Cancer Patients Nivolumab - Uterine Cancer, Endometrial Carcinoma | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 35 | 2017-08-03 | 2024-12-27 |
| Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma Sunitinib - Ovarian Cancer, Adverse Effects | Phase 2 | Completed | Cathay General Hospital | 30 | 2013-01-01 | 2018-07-18 |
| TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC) Erlotinib, Carboplatin, Paclitaxel - Non-Small Cell Lung Cancer, Lung Cancer | Phase 2 | Completed | M.D. Anderson Cancer Center | 68 | 2007-11-01 | 2019-11-20 |
| High-dose Bevacizumab in Advanced Renal Carcinoma Patients Bevacizumab - Renal Cancer, Kidney Cancer | Phase 2 | Completed | SCRI Development Innovations, LLC | 119 | 2007-02-01 | 2014-12-22 |
| Immunochemotherapy for Metastatic Renal Cell Carcinoma Capecitabine (Xeloda) - Adenocarcinoma Clear Cell | Phase 2 | Unknown | Rambam Health Care Campus | 45 | 2003-12-01 | 2006-01-04 |
| A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers Celecoxib - Uterine Cancer | Phase 2 | Terminated | Mark H. Einstein | 23 | 2003-04-01 | 2012-04-24 |
Ovarian Neoplasms (6) · Endometrial Neoplasms (3) · Fallopian Tube Neoplasms (3) · Carcinosarcoma (2) · Uterine Cervical Neoplasms (2) · Uterine Neoplasms (2) · Adenocarcinoma (1) · Carcinoma, Giant Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Small Cell (1) · Carcinoma, Squamous Cell (1) · Gastrointestinal Stromal Tumors (1) · Glioma (1) · Kidney Neoplasms (1)
Carcinoma (12) · Neoplasms (12) · Neoplasms by Histologic Type (12) · Neoplasms, Glandular and Epithelial (12) · Adenocarcinoma (11) · Neoplasms by Site (10) · Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9) · Urogenital Diseases (9) · Urogenital Neoplasms (9) · Genital Diseases (8) · Genital Diseases, Female (8) · Genital Neoplasms, Female (8) · Adnexal Diseases (6) · Endocrine Gland Neoplasms (6)
Bevacizumab (2) · Nivolumab (2) · Paclitaxel (2) · Capecitabine (1) · Carboplatin (1) · Celecoxib (1) · Doxorubicin (1) · Erlotinib Hydrochloride (1) · Gemcitabine (1) · Ipilimumab (1) · Radiotherapy (1) · Sunitinib (1) · dostarlimab (1) · liposomal doxorubicin (1) · pembrolizumab (1)
Brown University (1) · Cathay General Hospital (1) · Centre Oscar Lambret (1) · M.D. Anderson Cancer Center (1) · Mark H. Einstein (1) · Memorial Sloan Kettering Cancer Center (1) · North Eastern German Society of Gynaecological Oncology (1) · Rambam Health Care Campus (1) · SCRI Development Innovations, LLC (1) · Tufts Medical Center (1) · Xencor, Inc. (1) · Yonsei University (1)
United States (7) · Taiwan (2) · Australia (1) · Austria (1) · Belgium (1) · Czechia (1) · France (1) · Germany (1) · Hong Kong (1) · Israel (1) · Italy (1) · Japan (1) · Singapore (1) · South Korea (1) · Spain (1)
Chih-Ming Ho, Ph.D. (1) · Claire Friedman, MD (1) · Don Dizon, MD (1) · Eliahu Gez, MD (1) · Jalid Sehouli, Prof. Dr. med. (1) · John D. Hainsworth, M.D. (1) · Jolene Shorr (1) · Mark H Einstein, M.D., M.S. (1) · Steven H. Lin, MD, PHD (1)
PMID 25968826, PMID 38653864, PMID 39710508, PMID 39990653, PMID 42140839